Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions
P Moreau, E de Wit - British Journal of Haematology, 2017 - Wiley Online Library
The availability of novel therapies for the treatment of multiple myeloma has had a dramatic
impact on the depth of response that can be expected on initial treatment. Despite these …
impact on the depth of response that can be expected on initial treatment. Despite these …
A review of clinical guidelines, laboratory recommendations and external quality assurance programs for monoclonal gammopathy testing
SM Lim, N Wijeratne, KW Choy… - Critical Reviews in …, 2024 - Taylor & Francis
Monoclonal gammopathy (MG) is a spectrum of diseases ranging from the benign
asymptomatic monoclonal gammopathy of undetermined significance to the malignant …
asymptomatic monoclonal gammopathy of undetermined significance to the malignant …
Biological and clinical impact of the immunoglobulin light chain sequence diversity in patients with dominant heart AL amyloidosis
N Berghaus - 2024 - archiv.ub.uni-heidelberg.de
Immunoglobulins and their component light chains are essential parts of the human immune
system. Even though, in the context of an AL amyloidosis disease, light chains can be …
system. Even though, in the context of an AL amyloidosis disease, light chains can be …
[HTML][HTML] Development of a clinical diagnostic tool to differentiate multiple myeloma from bone metastasis in patients with destructive bone lesions (MM-BM DDx)
P Phinyo, T Maihom, A Phanphaisarn… - BMC Family …, 2020 - Springer
Background Most patients with destructive bone lesions undergo a comprehensive
diagnostic procedure to ensure that proper treatment decisions are pursued. For patients …
diagnostic procedure to ensure that proper treatment decisions are pursued. For patients …
Oligosecretory myeloma with amyloidosis and alopecia
A Bilal, P Der Mesropian, F Lam… - Journal of Investigative …, 2018 - journals.sagepub.com
Amyloidosis is a systemic illness characterized by the extracellular deposition of abnormal
proteins in body tissues and organs. In addition to renal involvement, amyloidosis can also …
proteins in body tissues and organs. In addition to renal involvement, amyloidosis can also …
[PDF][PDF] Diagnostic pitfalls of non-secretory myeloma: The biochemical perspective
RR Datta, A Awasthi - Journal of Clinical and Basic Research, 2024 - jcbr.goums.ac.ir
Non-secretory multiple myeloma (NSMM) is a rare myeloma subtype whose diagnosis is
established by demonstration of monoclonal plasma cells≥ 10% in the bone marrow and by …
established by demonstration of monoclonal plasma cells≥ 10% in the bone marrow and by …
[PDF][PDF] Plasmablastic light chain myeloma presenting as pancytopenia: An unusual presentation
P Agarwal, AS Nigam, V Kumar, S Marwah… - The National Medical …, 2017 - nmji.in
Light chain myeloma (LCM) is an unusual neoplasm accounting for about 18% of all plasma
cell myelomas. It is characterized by the absence of a detectable M protein in the serum and …
cell myelomas. It is characterized by the absence of a detectable M protein in the serum and …
[HTML][HTML] Nonsecretory Multiple Myeloma Presenting as Recurrent Vertebral Compression Fractures in an Older Male Patient
Nonsecretory multiple myeloma is a rare variant of multiple myeloma characterized by the
proliferation of clonal plasma cells in the bone marrow. It is difficult to establish an early and …
proliferation of clonal plasma cells in the bone marrow. It is difficult to establish an early and …
[PDF][PDF] The National Medical Journal of India
ABSTRACT Background. The Central Standard Drugs Control Organization (CDSCO)
issued an administrative order in November 2013 mandating audiovisual (AV) recording of …
issued an administrative order in November 2013 mandating audiovisual (AV) recording of …
[引用][C] A Case Report of Non-Secretorymyeloma with Renal Failure
Y Zhu, F Yan, B He, J Shen, Z Xiao - Clin Oncol, 2016